Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři	DOUBEK Michael TRBUŠEK Martin MALČÍKOVÁ Jitka BRYCHTOVÁ Yvona ŠMARDOVÁ Jana LOCHMANOVÁ Jana PANOVSKÁ Anna FRANCOVÁ Hana MRÁZ Marek TICHÝ Boris ŠEBEJOVÁ Ludmila NAVRKALOVÁ Veronika PLEVOVÁ Karla KUGLÍK Petr MAYER Jiří POSPÍŠILOVÁ Šárka
Rok publikování	2012
Druh	Článek v odborném periodiku
Časopis / Zdroj	Leukemia & Lymphoma
Fakulta / Pracoviště MU	Středoevropský technologický institut
Citace
www	http://informahealthcare.com/doi/abs/10.3109/10428194.2012.658794
Doi	http://dx.doi.org/10.3109/10428194.2012.658794
Obor	Onkologie a hematologie
Klíčová slova	chronic lymphocytic leukemia; p53 mutation; alemtuzumab
Popis	A poor prognosis in chronic lymphocytic leukemia (CLL) is associated particularly with the presence of del(17p) affecting tumor suppressor gene TP53. This deletion is in almost all cases of progressive leukemia accompanied by a mutation in the other TP53 allele, and in a smaller proportion of patients the TP53 mutation occurs also independently of del(17p). Recently, we demonstrated that patients with CLL harboring a missense mutation located in the p53 DNA-binding motifs (DBMs) (structurally well-defined parts of the DNA-binding domain) manifested a clearly shorter median survival in comparison with those having a missense mutation outside DBMs or a non-missense alteration. However, a limitation of this study resulted from the unpredictable survival impact of diverse therapy given to patients with p53 mutations. Th e therapeutic approach currently taken for patients with CLL with loss and/or mutation of TP53 relies mostly on the use of agents which do not act through DNA damage followed by apoptosis induction. Th e success of this approach has been documented for the monoclonal antibody alemtuzumab. Monotherapy with alemtuzumab is now being recommended as first-line therapy for patients with CLL with del(17p); however, many unresolved questions need to be addressed. For example, it is unclear whether the type of p53 mutation infl uences the outcome of alemtuzumab therapy.